Phase-III trials of the Covaxin vaccine from India's Bharat Biotech showed a 65.2% efficacy against the Delta variant, a 77.8% efficacy against symptomatic COVID-19, and a 93.4% efficacy against severe COVID-19. (Khaleej Times) COVID-19 pandemic in IndiaCOVID-19 pandemic in AsiaCOVID-19 pandemic link embed save